A Study of LY317615 in Patients With Brain Tumors

Lilly

Status and phase: Completed; Phase 2

Conditions: Malignant Glioma

Treatments: Drug: Enzastaurin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00190723

H6Q-MC-JCAJ

5799

Details and patient eligibility

About

1. The safety of LY317615 and any side effects that might be associated with the drug.
2. Whether LY317615, can help patients with brain tumors.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• You must be at least 18 years old
• You must have been diagnosed with a recurrent brain tumor by MRI or CT scan
• You must be able to swallow the LY317615 tablets

Exclusion criteria

• You are a woman who is pregnant or breastfeeding
• In view of your doctor, you have significant heart, liver, kidney, or psychiatric disease

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)